Enzymatica has entered into a distribution agreement with healthcare company Evergreen Health Ltd for sales and marketing of ColdZyme® Mouth Spray in Hong Kong and Macau. This is the second contract after Japan in Enzymatica’s expansion into Asia. Product sales are expected to begin in 2019.
Evergreen Health Ltd is part of Meiriki, a company that develops and sells various types of dietary supplements for the market in Hong Kong and Macau. Meiriki was founded in 1997 and has about 95 employees. The company, which sells products for vision, joint and cardiac problems, as well as products to strengthen immunity, is also a distributor for other Swedish life science companies.Meiriki has exclusive rights to the entire product range offered by the Watson pharmacy chain, one of the largest pharmacy chains in the world. Meiriki has received many awards for its products over the years, including “Best seller of Eye, Brain and Joint Health Product by Watsons for 14 consecutive years (2003-2016)”, as well as for its Corporate Social Responsibility (CSR) work.
Evergreen is now initiating the registration process for ColdZyme and plans to launch the product in Hong Kong and Macau in 2019. The company will carry out an extensive marketing campaign to introduce ColdZyme to the Hong Kong and Macau market.
The cold remedy market in Hong Kong and Macau is estimated at SEK 300 million and is growing at an annual rate of about 1 percent. Online sales are also increasingly growing. Today, the product range mainly consists of nasal sprays, cough medications, throat lozenges, decongestants and pain relievers.
For more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB Tel: +46 (0)708-86 53 70 | Email: email@example.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company’s first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit:www.enzymatica.com.
Enzymatica’s certified adviser is Erik Penser Bank.